Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revi ...

财报预期 - Idexx Laboratories (IDXX) 预计在即将发布的季度财报中，每股盈利将达到2.12美元，同比增长3.4%[1] - 分析师对于该季度的每股盈利预期在过去30天内下调了0.8%，显示出分析师整体上在这段时间内重新评估了他们的初始预期[2] 盈利预期修订 - 在公司发布财报之前，考虑盈利预期的修订非常重要，这是预测投资者对股票可能采取的行动的重要指标[3] 分析师预测 - 投资者通常依赖于共识盈利和营收预期来评估季度业绩，但深入分析分析师对某些关键指标的预测往往能提供更全面的理解[4]

IDEXX Laboratories, Inc. (IDXX) is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. A key element of IDEXX’s customer engagement strategy is the expansion of its commercial footprint in a disciplined approach. Robust demand for the company’s cloud-based offerings buoys optimism.However, negative solvency and foreign exchange fluctuations are discouraging for the company’s operations.In the past year, this Zacks Rank #3 (Hold) stock h ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Idexx Laboratories (IDXX) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This Animal diagnostic and health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 8.3 ...

IDEXX Laboratories, Inc. (IDXX) is set to release fourth-quarter 2023 results on Feb 5 before the opening bell.The company posted adjusted earnings per share (EPS) of $2.53 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 6.8%. IDEXX Laboratories beat earnings estimates in all the trailing four quarters, the average surprise being 7.64%.Let’s look at how things have shaped up before this announcement.Factors at PlayIDEXX’s Companion Animal Group (“CAG”) Diagnostics recurring rev ...

IDEXX Laboratories, Inc. (IDXX) recently expanded its Fecal Dx antigen testing platform with the addition of Cystoisospora —  a common intestinal parasite that is the source of diarrhea, weight loss and dehydration — primarily in young dogs and cats. Fecal Dx antigen testing with Cystoisospora will be offered at IDEXX Reference Laboratories in March in North America and globally in third-quarter 2024.The recent development will bolster IDEXX’s Livestock, Poultry and Dairy (LPD) business.More on Fecal Antige ...

新产品发布 - IDEXX Laboratories, Inc.宣布扩大其Fecal Dx®抗原测试平台，新增Cystoisospora，这是一种常见的肠道寄生虫，主要导致幼犬和幼猫出现腹泻、体重减轻和脱水[2] - Fecal Dx抗原测试可以比单独使用浮游虫检测方法检测到多达五倍的感染，通过识别寄生虫特异性抗原而不是依赖于卵的存在[3] - Fecal Dx抗原测试平台的第二次扩展将在不到两年的时间内实现，旨在提供准确检测最临床相关感染的全面解决方案[4]

AI-powered, load-and-go platform has potential to radically shift how veterinarians process, diagnose, and act on cytology and blood morphology casesThe global launch of the IDEXX inVue Dx analyzer will begin in late 2024WESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the IDEXX inVue Dx™ Cellular Analyzer, a first-of-its-kind slide-free cellular analyzer to detect the most common cytologic changes ...

财务数据和关键指标变化 - 第三季度有机收入增长8%,其中CAG诊断经常性收入增长9% [8][13] - 美国CAG诊断经常性收入有机增长8.3%,国际地区增长10.3% [16][20] - 整体利润结果超出预期,毛利率同比提升30个基点至59.9% [28][29] - 全年调整后EPS指引上调至9.74-9.90美元,维持高端水平 [42] 各条业务线数据和关键指标变化 - CAG诊断业务经常性收入增长9%,得益于仪器更换、新业务获取、高客户保有率等 [9][50] - 软件及影像诊断业务有机增长13%,云端软件部署持续增长 [25] - 水业务有机增长7%,得益于美国市场价格提升 [26] - 畜牧业务有机增长2%,受中国进口检测需求下降影响 [27] 各个市场数据和关键指标变化 - 美国临床就诊量同比下降2%,低于公司预期的相对平稳 [10][18] - 国际市场同店销售增长受到宏观环境影响,但仍实现10.3%的经常性收入增长 [20][62] 公司战略和发展方向及行业竞争 - 公司持续推进以高接触式商业模式、创新产品和软件解决方案为核心的战略 [47][50][65] - 公司在体外诊断和实验室服务领域保持领先地位,持续扩大全球商业版图 [54][63][79] - 公司计划于明年1月推出新的仪器平台,进一步丰富产品线 [72][73] 管理层对经营环境和未来前景的评论 - 宠物人口持续扩大,行业基本面向好,但短期内诊所人力管理挑战持续 [88][89][91] - 公司执行力强劲,各项关键指标表现良好,有信心应对当前挑战 [92][93][94] - 公司将持续投入创新,推动诊断频率和利用率的提升,为长期发展奠定基础 [47][50][65] 问答环节重要的提问和回答 问题1 **Michael Ryskin提问** 如果诊所就诊量持续低于预期,对公司长期模型会有什么影响? [85][86] **管理层回答** 行业基本面向好,公司执行力强劲,有信心应对短期挑战,并持续推进创新以支撑长期发展 [88][89][92][93] 问题2 **Erin Wright提问** 新平台的测试进展如何?明年是否会有重大贡献? [120][121] **管理层回答** 新平台即将在1月份发布,具体情况届时会详细介绍,但不会提供更多细节 [121][122][123] 问题3 **Chris Schott提问** 诊所就诊量下滑是否主要受宏观因素还是诊所自身产能影响? [132][133][134] **管理层回答** 主要是诊所自身产能管理挑战,宏观因素对wellness就诊量有一定影响 [134][135][136][137][138]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Dela ...